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Abstract: Lipid–polymer hybrid nanoparticles (LPHNPs) are next-generation core–shell 
nanostructures, conceptually derived from both liposome and polymeric nanoparticles (NPs), 
where a polymer core remains enveloped by a lipid layer. Although they have garnered significant 
interest, they remain not yet widely exploited or ubiquitous. Recently, a fundamental transforma-
tion has occurred in the preparation of LPHNPs, characterized by a transition from a two-step 
to a one-step strategy, involving synchronous self-assembly of polymers and lipids. Owing to 
its two-in-one structure, this approach is of particular interest as a combinatorial drug delivery 
platform in oncology. In particular, the outer surface can be decorated in multifarious ways for 
active targeting of anticancer therapy, delivery of DNA or RNA materials, and use as a diagnostic 
imaging agent. This review will provide an update on recent key advancements in design, syn-
thesis, and bioactivity evaluation as well as discussion of future clinical possibilities of LPHNPs.
Keywords: lipid–polymer hybrid nanoparticle, lipid-based nanoparticle, polymer-based 
nanoparticles, drug delivery, gene delivery
Introduction
Nanotechnology is a compelling medicinal platform with the potential to greatly impact 
the delivery of a plethora of therapeutics, encompassing small molecule therapeutics, 
genes, RNAs, peptides, and diagnostic imaging agents, as well as holding great prom-
ise for improving the therapeutic index and pharmacokinetics of several drugs under 
systemic settings.1–4 In general, these payloads are encapsulated within or covalently 
grafted on the surface of the nanocarriers, and after being systemically incorporated, 
their release is monitored by factors such as formulation of the matrix, pH of the 
microenvironment, and temperature of the surroudings.5–7 The inherent potential of 
nanoparticles (NPs) for therapeutic cargo delivery is primarily attributable to few key 
parameters, including average nanometric size, homogeneity, surface potential, and 
drug loading, among others.8,9 Surface-coated immuno-inert NPs can also skillfully 
bypass the reticuloendothelial system yielding increased bioavailability of encapsu-
lated drugs.10 The plausible advantages of nanocarriers are summarized as follows: 
1) improvement to a drug’s overall pharmacokinetic and pharmacodynamic properties 
without alteration of its molecular structure; 2) enhanced effective tissue targeting, 
cellular targeting, and molecular targeting; 3) the ability to circumvent many inherent 
biological impediments; 4) targeted and nontargeted drug delivery to their respec-
tive site of action (cytosol, nucleus, etc) and enhanced therapeutic index of the drug; 
5) delivery of multiple drugs with differing chemical properties.11,12
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In the last few decades, an increasing amount of 
nanotechnology-based products have begun clinical trials – 
including liposomes, polymeric NPs, albumin NPs, and inor-
ganic NPs – of which a small number have already been 
accepted for clinical use.13–17 Among these nanocarrier types, 
the two best characterized are liposomes and polymeric NPs.
Liposomes are artificial “fat bubbles”, ie, vesicles, char-
acterized by having one or more bilayers spontaneously 
achieved by dispersal of natural or synthetic amphiphatic 
lipids in water. Since their discovery, they have largely been 
exploited as delivery vehicles because of their biocompat-
ibility and advantageous safety profile. Their surface can be 
modified by attaching polyethylene glycol (PEG) which, in 
turn, prolongs circulation half-life.18,19 Doxil and Myocet, 
two leading doxorubicin liposomes, received Food and Drug 
Administration (FDA) approval in 1995 and 1999, respec-
tively, followed later by others of the same category.20 To 
date, around 16 liposomal drugs are clinically approved and 
a few of those are marketed, such as AmBisome (amphoteri-
cin B), DaunoXome (daunorubicin), DepoCyt (cytarabine), 
DepoDur (morphine), and Visudyne (verteporfin).15 Despite 
clinical approval, until recently no FDA-approved liposomal 
drugs showed significant overall survival (OS) improvement 
over the parent drug.21 In a 2017 study, phase III outcomes of 
liposomal combination drugs such as cytarabine–daunorubi-
cin (Vyxeos; CPX-351), as contrasted with their individual 
counterpart cytarabine and daunorubicin (“7+3”) in 60- to 
75-year-old patients with high-risk acute myeloid leukemia, 
revealed enhanced OS of 9.56 vs 5.95 months.22
Polymeric NPs, on the contrary, can be manufactured (via 
nanoprecipitation or the double emulsion method) by self-
assembly of biodegradable amphiphilic block copolymers 
with varying hydrophobicities and are appropriate for sys-
temic administration. The core–shell structure of polymeric 
NPs facilitates encapsulation of hydrophobic drugs and 
sustained drug release and extends circulation time. Their 
surfaces can also be decorated with ligands for targeted drug 
delivery.23,24 For instance, Genexol-PM is a polymer-based 
NP formulation of paclitaxel (PCX) and poly (d,l-lactide)-
b-polyethylene glycol-methoxy (PLGA-mPEG), which has 
been approved for metastatic breast cancer therapy in Korea 
and the European Union.25,26
In order to utilize the unique attributes of liposomes and 
polymeric NPs that led to their initial clinical success, but 
overcome limitations like structural disintegration, limited 
circulation time, and content leakage, a new progeny of 
delivery system has been developed: lipid–polymer hybrid 
nanoparticles (LPHNPs).27 The hybrid system can be a sturdy 
drug delivery rostrum with high encapsulation efficiency, 
well-defined release kinetics, well-tolerated serum stability, 
and well-triggered tissue, cellular, and molecular target-
ing properties. In this article, we will review the emerging 
innovations of LPHNPs, incorporating new developments 
in their production strategies and drug delivery applications 
in cancer therapy.
Structure elucidation and mechanism 
of hybrid formation
As can be inferred from their name, LPHNPs merge the 
features of both polymeric NPs and liposomes. They consist 
of three building blocks as illustrated in Figure 1. These are 
1) a polymer core encapsulating the drug, 2) a lipid mono-
layer surrounding the polymer core, and 3) an outer lipid–
PEG layer, a steric stabilizer prolonging systemic circulation 
of the LPHNPs by evading immune destruction. The middle 
lipid monolayer behaves like a molecular barricade that 
mitigates the loss of entrapped drugs over the course of the 
LPHNP formulation and protects the core from degradation 
by preventing the diffusion of water into the inner core.27,28
The molecular mechanics of fusion between lipid and 
polymer is still under investigation. It is apparent that dis-
tinguished methods of LPHNP manufacturing have differ-
ent mechanisms of formation. For instance, in single-step 
methods, the polymer precipitates from the organic solvent 
when added to aqueous media containing lipids, which 
subsequently spontaneously self-assemble into a monolayer 
surrounding the core. PEGylated lipids also self-assemble 
/LSLGVKHOO(QFDSVXODWHGGUXJ3RO\PHUFRUH
/LSLG±3(*
$QWLERG\5*')RODWH 7UDQVIHUULQ
Figure 1 Structure of a lipid–polymer hybrid nanoparticle (LPHNP) comprises of 
a polymer core encapsulating a pay load, a lipid shell, and an outer lipid–PeG layer.
Note: The lipid–PeG layer can also be conjugated to a variety of targeting agents, 
such as folic acid, arginylglycylaspartic acid (RGD), or antibodies, to ensure 
targeted delivery.
Abbreviation: PeG, polyethylene glycol.
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during this step, wherein a lipid moiety clings onto the surface 
of the polymer core and the PEG chain extends externally 
toward the aqueous environment. During the two-step 
method, a plausible mechanism of LPHNP formation may 
involve an initial bilayer structure formation and adherence 
to the core, with subsequent disintegration of the bilayer 
owing to the hydrophobic interaction between polymer and 
lipid chains. The hybrid formation is thermodynamically 
favorable, with respect to hydrophobic, van der Waal, and 
electrostatic interactions.29,30
Methods for preparation of LPHNPs
Two-step method
Conventional method
During initial days of study, a typical two-step method was 
frequently employed to form LPHNPs, wherein preformed 
polymeric NPs were mixed with preformed lipid vesicles and 
the latter was surface-assimilated onto the former, propelled 
by electrostatic forces. The polymeric NPs are generally 
prepared by nanoprecipitation,31 emulsification–solvent 
evaporation (ESE),32 or high-pressure homogenization.33 
As depicted in Figure 2, the two-step method can be subcat-
egorized into two types: A) direct addition of the previously 
formed polymeric NPs to dried lipid film, or B) preformed 
NPs added to preformed lipid vesicles, made by initial 
hydration of the thin lipid film. In either case, the hybrids 
are assembled by the input of external energy via vortexing 
and/or ultrasonication of the suspension and heating at a 
temperature beyond the phase transition temperature of the 
lipid constituent. In purification step, free lipid and LPHNPs 
are separated by differential centrifugation. For instance, 
a method was developed for hybrid NP preparation using 
PLGA combined with cationic lipid vesicles (FA-OQLCS/
PEG-OQLCS/Chol) under continuous stirring or bath soni-
cation at 30°C, yielding stable LPHNPs with average sizes 
between 200 and 400 nm and a surface potential of (+) 
20–30 mV.32,34 Using different precursors, Thevenot et al and 
Troutier et al utilized a similar method to make LPHNPs.31,35
In order to obtain a homogeneous NP suspension with 
unimodal particle distribution, hybrid NPs undergo sequential 
extrusion and/or homogenization after preparation. While 
extruding the sample, as normally practiced in the laboratory, 
the NP suspension is downsized by passing them through 
a porous membrane. For example, Messerschmidt et al 
created tumor necrosis factor (TNF)-functionalized hybrid 
NPs using polystyrene as the core and shell made up of egg 
phosphatidylcholine (egg-PC), cholesterol, DSPE–mPEG, 
and maleimide-DSPE–mPEG. The resultant NPs were down-
sized by extruding through a 200 nm porous membrane.36 
This technique was also employed by Hu et al to construct 
Homogenization:
ultrasonication,
vortexing, etc
Thin lipid film
Hydration with
aqueous solvent
B
A
Aqueous
polymeric
nanoparticle
suspension
Formation of
lipid vesicles
Polymeric nanoparticle
Aqueous
polymeric
nanoparticle
suspension
Lipid polymer
nanoparticles
Thin lipid film
Preformed lipid
vesicles
Figure 2 The two versions of lipid–polymer hybrid nanoparticle preparation via the two-step method.
Notes: (A) The aqueous polymeric nanoparticle suspension is directly added to the dried lipid film. (B) Thin lipid film is first hydrated with an aqueous solvent to facilitate 
the formation of lipid vesicles. The hydrated vesicles are then combined with an aqueous preformed nanoparticle suspension. For either technique, the hybrids are then 
produced via vortexing or ultrasonication of the mixture at a temperature greater than the phase transition temperature of the lipids.
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a red blood cell membrane-coated NPs (~120 nm) and 
by Sengupta et al to produce chemotherapeutic LPHNPs 
(~200 nm).37,38 As a substitute, some other groups explored 
homogenization to formulate unimodal LPHNPs (~60 nm) 
made up of a maltodextrin polysaccharide core and a DPPC/
Chol lipid shell.33,39
Nonconventional method
Aside from the abovementioned methodologies, few other 
methods going beyond convention have also been imple-
mented to manufacture LPHNPs. For example, polymeric 
NPs (ie, polyglutamic acid, polylysine) of average size 
400–500 nm were produced by spray drying, dispersed in 
DCM containing the lipids (tripalmitin, tristearin, cetyl alco-
hol). This suspension was later spray-dried again to prepare 
LPHNPs of size range 0.9–1.2 µm with aspray dryer that 
was inappropriate for the production of NPs.40 The recently 
marketed nanometric spray dryer can be used to produce 
smaller hybrid NPs as well.41
Additionally, in recent years, a particle molding method 
by soft lithography called particle replication in nonwetting 
templates (PRINT) was explored to prepare LPHNPs for the 
delivery of genetic materials.42
Optimization of formulation parameters
The physical characteristics of LPHNPs (average size, col-
loidal stability, polydispersity) prepared by the two-step 
method are majorly regulated by the following formulation 
parameters: 1) preformed lipid vesicle size and polydisper-
sity index (PDI), 2) surface potential of the outer lipid shell, 
3) ionic strength of the aqueous phase, 4) lipid-to-polymer 
ratio, and 5) PEG chain length and mol% of PEG–lipid.31,35 In 
particular, extrusion-produced particles are smaller and more 
homogeneous compared with that generated by direct lipid 
film hydration with polymer solution. Moreover, homogene-
ity of LPHNPs is critically dependent on the charge of the 
lipid vesicles. As such, least particle aggregation with high 
colloidal stability and narrow PDI was attained by using only 
one lipid type to form the vesicles, ie, only the zwitterionic 
lipid DPPC or the cationic lipid DPTAP. On the contrary, 
aggregation-prone LPHNPs have been formed when both 
DPTAP and DPPC were used, the mechanism of which 
could be attributed to the electrostatic interactions between 
the two types of lipids.35 Separately, hybrid particles’ col-
loidal stability was notably impacted by lipid to polymer ratio 
(A
V
/A
P
). At high lipid to polymer A
V
/A
P
 and high cationic 
lipid concentration, the lipid layer may potentially act as 
electrostatic stabilizer. At low A
V
/A
P
 and low fractions of 
cationic lipid, partial lipid coating of the polymer core was 
insufficient to stabilize the LPHNP. The anionic surface of 
the core of one hybrid molecule was exposed to the cationic 
DPTAP of another hybrid leading to the agglomeration of 
LPHNPs. Intriguingly, with DPPC alone, the hybrid NPs 
were less susceptible to agglomeration even at low A
V
/A
P
. 
This can again be credited to the zwitterionic nature of DPPC 
reducing the possibility of electrostatic interactions.35
Similar to liposomes, a drawback of LPHNPs is their 
weak colloidal stability relative to the ionic strength of the 
solution; electrostatic interactions alone cannot stabilize 
hybrid particles in aqueous medium with .10 mM NaCl 
ionic strength. Again, like liposomes, this is mitigated by 
incorporating conjugated PEG–lipids into the lipid mixture 
(DPPC/DPTAP) to impart stabilizing PEG chains onto the 
surfaces of the LPHNP. To envisage the most advanta-
geous conditions to attain colloidal stability, Thevenot 
et al thoroughly investigated the effects of the PEG chain 
length (n=16, 45, and 113) and mol% (1%, 5%, and 10%) of 
PEG–lipid in lipid formulation, where the polymer core was 
made up of PLA and lipid layers were comprised of DPTAP, 
DPPC, and PEG–phosphoethanolamine (PEG–PE). Keeping 
the lipid composition unchanged (DPPC:DPTAP:PEG–
PE=40:50:10% w/w), and upon gradual increase in the degree 
of polymerization in the PEG chain, they observed that the 
mol% of the PEG–lipid inhabiting the lipid shell decreased 
with stretching chain length from ~3% for n=16 and 45 to 
~2% for n=113. The observation was ascribed to spatial repul-
sion between the bulky lipid–PEG shells with longer PEG 
chains. Importantly, thickness of the lipid layer adsorbed onto 
PLA particles was increased with the amount of PEG–lipids 
adsorbed or with the PEG chain length, from 67 Å at n=16 to 
98 Å at n=113. This resulted in an increased charge screening 
effect, which subsequently lowered the zeta potentials from 
(+) 51 mV at n=16 to (+) 22 mV at n=113. This is owed to 
a transition from mushroom-like confirmation to outward 
brush-like confirmation. In accordance with the quasi-elastic 
light scattering (QELS) study, the n=16 PEG shell was not 
adequate enough to be effectively sterically stabilizing. The 
n=45 PEG shell showed moderate stabilization, while the 
n=113 PEG shell displayed the best colloidal stability for the 
hybrid NPs. Thickness of the lipid shell increased from ~52 
Å at 1% PEG–PE to 79 Å at 10% PEG–PE, and this lowered 
the zeta potentials from (+) 47 to (+) 26 mV, respectively.31
Apart from average size, PDI, and surface potential 
(which is a measure of colloidal stability), other impor-
tant formulation parameters are % drug loading (%DL), 
% encapsulation efficiency (%EE), and in vitro release 
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kinetics of the drug from the LPHNPs. For example, 
Mieszawska et al demonstrated an %EE =85% w/w and 
%DL =11% w/w for their anticancer drug.32 Hasan et al 
also showed an %EE =32%–46% w/w for siRNA using 
the PRINT method.42 This is worth mentioning because 
for LPHNPs prepared by the two-step method, %EE of the 
drug is majorly determined by the formulation parameters 
of the polymeric core, which has been extensively explored 
in previous studies; similar trends are followed when the 
same polymer was used for the LPHNP formation.43
One-step method
The limitation of the two-step method is that preparing 
polymeric NPs and lipid vesicles separately makes the 
process inefficient in terms of energy and time spent. The 
commonly available and more efficient alternative is a one-
step method. Preformed lipid vesicles and polymeric NPs 
are not prerequisites for the one-step method. The method 
solely requires mixing of lipid and polymer solutions that 
subsequently tend to self-assemble to form LPHNPs. The 
most common processes are nanoprecipitation and/or ESE, 
both of which are often implemented for the production of 
nonhybrid polymeric NPs. Here, the lipids/PEG–lipids used 
function as stabilizing agents for the hybrid produced, while 
ionic or nonionic surfactants (PVA, DMAB, poloxamer) are 
generally used as stabilizers in the preparation of regular, 
nonhybrid polymeric NP.
Nanoprecipitation
Traditional nanoprecipitation method requires that the drug 
and polymer are dissolved together in a water-miscible 
organic solvent (viz, acetone, EtOH) and the lipid/lipid–PEG 
dissolved in water. It is mandatory to heat the lipid/lipid–PEG 
solution beyond its gel-to-liquid transition temperature in 
order to achieve a homogeneously dispersed liquid crystalline 
phase. This is followed by drop wise addition of the polymer 
to the aqueous dispersion of lipid under continuous stirring. 
This triggers the polymer to coil into NPs with concurrent 
self-assemblage of the lipids surrounding the polymer owing 
to hydrophobic interactions, where hydrophobic tails of the 
lipids are directed toward the inner NP and the hydrophilic 
head groups face out toward the external aqueous solution. 
The hydrophobic lipid tails of the lipid–PEG merge into the 
inner lipid shell, while its PEG chains pop out to the aqueous 
environment, sterically stabilizing the hybrid.27 The organic 
media is evaporated and the LPHNPs, thus formed, are 
centrifuged (Figure 3). A promising noninvasive delivery 
of mRNA-based vaccines, developed recently, involves 
postinsertion of the PEGylated lipid vesicles following 
nanoprecipitation.44
A few novel approaches are being adopted by a number 
of research groups to improve upon one-step methods. 
For example, using a bath sonication approach, Fang et al 
demonstrated a rapid synthesis (~5 minutes) of hybrid NPs 
with small and nearly uniform size.29 In 2010, Valencia et al 
Figure 3 Nanoprecipitation technique for the preparation of LPHNPs by one-step method.
Notes: Drug and polymer are dissolved together in a water-miscible solvent, such as ethanol or acetone. The lipids and/or lipid–PeG are dissolved together in water, and 
the solution is heated beyond the lipids respective gel-to-liquid transition temperature. The polymer/drug solution is then added drop-wise to the lipid dispersion during 
continuous stirring, triggering the precipitation of the nanoparticles and the aggregation of the lipids/lipid–PeGs around the NP core due to hydrophobic interactions.
Abbreviations: LPHNPs, lipid–polymer hybrid nanoparticles; NP, nanoparticle; PeG, polyethylene glycol.
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reported the use of microfluidics, where two phases are 
rapidly mixed using hydrodynamic flow, directly generating 
homogeneous NPs with relatively narrow size distribution.45 
Fang et al, again in 2012, came up with a multi-inlet vortex 
reactor for scale up of LPHNPs.46 To address the issues 
with low throughput of microfluidics, Kim et al developed a 
pattern-tunable microvortex platform for scale up of LPHNPs 
as well. The microvortex platform could restrict the average 
size of NP between ~30 and 170 nm with low PDI (~0.1) 
and high productivity (~3 g/hour) by varying flow rates 
(ie, Reynolds number [30–150]).47
Optimization of formulation parameters in 
nanoprecipitation
The unanimous formulation parameter indicated in many 
studies as having the most prominent effect on the charac-
teristics of an LPHNP is the stoichiometry, ie, the lipid to 
polymer mass ratio (L/P ratio). In two consecutive studies 
performed in O C Farokhzad’s laboratory, the L/P ratio 
was optimized to be 15% (w/w) for optimal covering of the 
polymer, where PLGA was used as the polymer and lecithin 
plus DSPE–PEG as the lipids, to generate stable mono-
disperse LPHNPs (60–80 nm).27,48 This optimization was 
crucial as higher L/P (w/w) ratios led to lipid concentrations 
greater than the CMC (critical micelle concentration of the 
polymer), which could lead to the formation of liposomes 
in addition to hybrids, while lower L/P (w/w) ratios led 
to agglomeration. Similarly, cationic LPHNPs of average 
size ~65 nm were prepared by single-step nanoprecipitation 
of a cationic lipid (BHEM-Chol) and amphiphilic polymer 
mPEG–PLA for systemic delivery of siRNA, where optimal 
L/P ratio was reported to be 10% (w/w).49 Intriguingly, as 
demonstrated by Zheng et al, in the absence of lipid–PEG, 
a huge excess of lipid (egg-PC/DOPE lipid shells with 
D-α-TPGS) was needed in the formulation leading to an 
optimum L/P ratio of 428% (PLGA-to-lipid ratio of 3.5/15), 
to form hybrid NPs with relatively higher average size 
(150–190 nm).50
A salient feature of the lipid coating (reflected as L/P 
ratio), as discussed in structure elucidation, is to protect 
the polymer core. This indirectly regulates %EE and drug 
release.27 In contrast, for nonhybrid polymeric NPs, the 
polymer’s physicochemical property is the sole influence 
on %EE and release kinetics.51 At the optimal L/P ratio 
(15% w/w), LPHNPs showed higher %EE of the docetaxel 
(59%±4%) compared with its nonhybrid counterparts PLGA 
NPs (37%±4%) and PEGylated-PLGA NPs (19%±3%). 
A longer sustained release of the drug (50% in 20 hours) 
was shown by LPHNPs compared with that of PLGA and 
PLGA-PEG NPs (50% in 7 and 10 hours, respectively).27
The colloidal stability of LPHNPs (prepared either by 
one-step or two-step method) is contingent on the lipid–PEG 
present in the lipid formulation. In the absence of PEG-
grafted lipid, despite reasonably high L/P ratio, lecithin-
coated PLGA NPs were shown to be unstable when they 
formed large aggregates (~2 µm) in PBS, hinting at the 
inability of the lipid layer to stabilize the formulation.48 With 
the addition of DSPE–PEG, the LPHNPs became stable in 
PBS as the PEG chains conferred steric stabilization. By 
enhancing the PEGylated lipid in the lipid formulation, 
more stable hybrid NPs were yielded, where the optimal 
lipid–PEG amount was found at ~25% (w/w). Importantly, 
higher concentration of PEG on the particle surface did not 
alter the release kinetics or %EE.48,52,53
Nonetheless, PEG fraction present in the formulation 
does influence the average size of LPHNPs. For example, 
according to the study performed by Zheng et al, a decrease 
in the LPHNP size (from 230 to 150 nm) with increasing PEG 
fraction was observed.50 Be that as it may, other formulation 
parameters, viz, concentration and molecular weight of poly-
mer, and water-to-solvent ratio have similar effects on the 
size of nonhybrid polymeric NPs as well as hybrid NPs.27,48,53
Emulsification–solvent evaporation
This method can further be subclassified into single and dou-
ble emulsification methods as depicted in Figure 4A and B, 
respectively. A single ESE method (Figure 4A) is used for 
drugs soluble in hydrophobic solvents (oil phase). In this 
method, an oil-in-water (o/w) emulsion is formed when 
the water-immiscible oil phase containing the polymer and 
the drug is mixed with an aqueous phase containing dis-
solved lipid under ultrasonication or constant stirring. Next, 
the polymer core is formed by evaporation of the organic 
media and the lipids assemble around the polymer core 
concomitantly.54 As an ostensible replacement, the lipid can 
concurrently be dissolved in the oil phase with the polymer.55 
A double ESE method (w/o/w) is applied for water-soluble 
drugs (Figure 4B). First, the aqueous solution of the drug is 
emulsified in an organic solvent (oil phase) containing poly-
mer and lipid to form a w/o mixture. A w/o/w emulsion is 
generated when the mixture is emulsified again in an aqueous 
phase containing the lipid–PEG, followed by subsequent oil 
phase evaporation, to yield the LPHNPs.55 As evident from 
Figure 4B, the hybrids produced by the double ESE method 
contain certain structural anomalies. It is composed of 1) an 
inner aqueous core surrounded by lipid layer, 2) a polymer 
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$ %
,QQHUOLSLGVKHOO3RO\PHUOD\HU3RO\PHUFRUHFRQWDLQLQJK\GURSKRELFGUXJ /LSLGVKHOO
Figure 4 LPHNPs produced by the emulsion-solvent evaporation (eSe) method.
Notes: (A) Single eSe method utilized for a hydrophobic drug (soluble in oil phase). water-immiscible solvent is used to dissolve drug and polymer. The resulting solution is 
added to lipid/lipid–PeG containing aqueous phase under agitation to form an oil/water emulsion. The oil phase is evaporated out, along with simultaneous formation of the 
polymer core and lipid shell. (B) Double ESE method is employed for hydrophilic (water-soluble) drugs. An aqueous solution of drug is emulsified in organic solvent containing 
polymers and lipids, under constant stirring. This w/o emulsion is again emulsified in an aqueous solvent containing the lipid–PEG, forming a w/o/w emulsion. Evaporation of 
oil phase leads to LPHNP formation.
Abbreviations: LPHNPs, lipid–polymer hybrid nanoparticles; PeG, polyethylene glycol.
layer in between, and 3) an outer lipid–PEG shell. Generally, 
the ESE method produces LPHNPs that are larger than those 
produced by conventional nanoprecipitation.
Optimization of formulation parameters in eSe
Resembling nanoprecipitation, L/P ratio is the most promi-
nent among all formulation parameters to govern ESE 
method. Using PLGA, TPGS, and PC, Cheow and Hadinoto 
found a reduction in size with increase in L/P ratio and 
achieved a standard production yield (w/w).55 Liu et al 
achieved similar results with the single ESE method using 
PLGA and 1,2-dilauroylphosphatidylocholine (DLPC).56 
Bershteyn et al demonstrated that excess lipid in the system 
(high L/P ratios) resulted in either multilamellarity of lipid 
layer or spontaneous precipitation of the lipids as liposomes.54 
Here also, the L/P ratio was shown to have an influence on 
%EE. The optimal lipid concentration in terms of smaller 
size and high %EE was 0.04% (w/v).56 Interestingly, the 
ESE method typically resulted in higher %EE than that 
of nanoprecipitation due to larger particles produced. For 
example, polymer remaining same, nanoprecipitation yielded 
%EE ~20% (w/w) for PCX in ~50–60 nm LPHNPs,48 while 
ESE method yielded %EE ~60% (w/w) in ~200–300 nm 
particles.56 In 2011, a novel one-pot synthetic method was 
developed for ESE. Using PLGA as the core, and either 
cetyltrimethylammonium bromide or PEG–DSPE as an 
emulsifier, hybrid particles of $50 nm were produced, which 
also possessed high %EE.57 Cheow and Hadinoto, exploiting 
fluoroquinolone antibiotics as a model, proved that ionic 
interactions between the drug and the lipid are crucial in the 
preparation of LPHNPs by ESE method.55
Advances in drug delivery 
applications of LPHNPs
Given the large number of potential drug delivery applica-
tions that exist, there is great interest in exploring uses of the 
LPHNP platform in future clinical studies. Here, we discuss 
few important recent advancement made in the field and areas 
of future interest.
Nontargeted combinatorial drug delivery 
approach
Besides having an array of single drug delivery strategies 
via LPHNPs (eg, in chemotherapy27,48,56 and antibiotic 
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treatment58–60), significant endeavors have been directed 
toward development of a combinatorial approach for cancer 
therapeutics. Truly effective cancer treatment regimens often 
require multiple chemotherapeutic drugs used in tandem or 
chemotherapeutic drugs administered in combination with 
targeting therapeutic agents.61
However, a pertinent question arises as to how best to 
maximize the efficacy of NP-mediated delivery of therapeutic 
payload: codelivery from a single nanocarrier or two different 
carriers? It has been proposed by many that a single biocom-
patible nanocarrier capable of carrying more than one agent 
in particular stoichiometry and releasing them in a sustained 
way may hold the most promise. We provide a brief account 
of several strategies that have already been employed to 
accomplish successful combinatorial drug delivery exploring 
the potential of LPHNP platform (Table 1).
Two major obstacles of antiangiogenic cancer therapy 
include 1) not allowing tumor to obtain an effective con-
centration of the chemotherapeutics and 2) induction of 
tumor hypoxia, resulting in chemoresistance and enhanced 
invasiveness. To address these issues, Sengupta et al came 
up with a hybrid nanocell where the core was comprised of 
DOX-conjugated PLGA and the envelope was made up of 
PC-Chol-DSPE–PEG entrapping combretastatin-A4 (for 
vascular closure) and validated its therapeutic efficacies in the 
murine model of melanoma and Lewis lung carcinoma.37 In 
2013, Zheng et al, to accomplish combined chemo-photother-
mal therapy, successfully synthesized PLGA-lecithin-PEG 
hybrid NPs by a single-step sonication method, which could 
simultaneously deliver DOX and indocyanine green (ICG) 
to the tumor microenvironment. It induced apoptotic cell 
death to DOX-sensitive MCF-7 or DOX-resistant MCF-7/
ADR in vitro and inhibited MCF-7 or MCF-7/ADR tumor 
growth and inhibited tumor recurrence under systemic 
settings.62 To surmount the immunoinhibitory property of 
the tumor microenvironment, Park et al synthesized hybrid 
NPs comprised of SB505124-entrapped cyclodextrins and 
cytokine-encapsulating PLGA within a PC-Chol-DSPE–PEG 
shell, which can simultaneously deliver both agents to the 
tumor microenvironment. As reported, sustained release of 
TGF-β receptor-I inhibitor and IL-2-inhibited tumor growth 
significantly enhanced survival of tumor-bearing mice and 
enhanced the natural killer cell activity and CD8+ T-cell 
infiltration.63 In order to sensitize intrinsically (and acquired) 
cisplatin-resistant tumors, Xu et al prepared a hybrid NP with 
a cationic lipid-like molecule and PLGA-PEG for codelivery 
of cisplatin prodrug and siRNAs targeting the REV1, REV3L 
genes, which are engaged in the modification-susceptible 
translesion DNA synthesis pathway. Importantly, after a 
single dose, a remarkably sustained (up to 3 days) downregu-
lation of both the genes was measured by real-time qPCR. 
Systemic administration of these NPs displayed synergisti-
cally inhibited tumor growth in a human metastatic lymph 
node carcinoma of the prostate xenograft mouse model, 
outcompeting Pt monotherapy.64 Again in 2013, Deng et al 
designed and synthesized layer-by-layer hybrid NPs to code-
liver an MRP1 siRNA that downregulates a drug-resistant 
pathway and DOX to treat triple negative breast cancer in an 
MDA-MB-468 xenograft model. It turned out to be a potent 
combination therapy in their study, emphasizing the poten-
tial of layer-by-layer NPs as a multitherapeutic platform for 
combinatorial therapy.65 In another study, to obtain improved 
synergistic effect by sequential and site-specific delivery, 
Jiang et al reported a nanodepot, where the core is a liposome 
encapsulating DOX in the aqueous interior, and an outer 
shell comprised of cross-linked hyaluronic acid entrapping 
a TNF-related apoptosis-inducing ligand. Substantial tumor 
growth inhibition was found in the MDA-MB-231 murine 
xenograft model.66
To achieve a concurrent treatment of chemotherapy and 
radiotherapy, using nanoprecipitation method, Wang et al 
developed small LPHNPs named ChemoRad coencapsulat-
ing chemotherapeutic (docetaxel) in the PLGA core and 
radiotherapy agents (indium-111 or yttrium-90) chelated 
to a 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
diethylene-triamine-penta acetate (DMPE–DTPA) lipid 
shell. As per their report, absorption of radioactive isotopes 
was not detrimental toward encapsulation and release of the 
drug. Within 45 minutes, particles were taken up by LNCaP 
prostate cancer cells and showed enhanced cytotoxicity over 
their single counterparts.67 Concurrent incorporation of two 
chemotherapeutic drugs (doxorubicin and camptothecin) 
into a single LPHNP system was also achieved by covalent 
grafting of the drugs with the polymer. Aryal et al synthesized 
DOX-PLA and CPT-PLA conjugates, adjusted their molar 
ratio, and enveloped them by egg-PC-DSPE–PEG-COOH 
using a nanoprecipitation method.68 In a similar way, PCX-
gemcitabine69 and PCX-cisplatin70 conjugates were prepared 
and loaded onto LPHNPs.
Active-targeted drug delivery
In recent years, cancer research has increasingly focused on 
receptor-mediated active-targeted drug delivery to decrease 
off-site chemotherapy toxicities and increase drug accu-
mulation in target tumor cells. This has been achieved by 
functionalizing NPs (drug delivery systems) with the ligand 
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(targeting moieties) for a particular receptor (eg, folate, 
integrin, transferrin) overexpressed in specific cancer 
cells.71 In the following section, we will discuss different 
methods utilized for surface modification followed by active 
targeting (Table 2).
Folate-mediated delivery
In 2015, Wu et al synthesized a reduction-sensitive biode-
gradable hybrid NP, targeted with a folate ligand, to deliver 
DOX. The NP was comprised of a PLGA core, a soybean leci-
thin and monomethoxy-poly(ethylene glycol)-S-S-hexadecyl 
(mPEG-S-S-C16) monolayer, and DSPE–PEG-folate and 
prompted a faster release of DOX in the presence of 10 mM 
dithiothreitol. Owing to receptor-mediated endocytosis, these 
particles enhanced cellular uptake and cytotoxicity in folate-
overexpressing human oral cavity squamous carcinoma 
cells (KB cells) and showed greater tumor accumulation 
and appreciable antitumor efficacy in KB cells xenografted 
into BALB/c nude mice.72 Folic acid was also selected as 
a ligand for targeted delivery of docetaxel to certain breast 
cancer and ovarian cancer cells by Liu et al in 2010, where 
their LPHNP was composed of a PLGA core, DLPC to 
envelop, DSPE–PEG
2000
 for stealth and DSPE–PEG
5000
-
folate for active targeting. NPs were tuned for stoichiometric 
management of the targeted delivery, were stable with desired 
surface property, and showed long half-life in plasma.73 With 
a view to harness a combined outcome of chemotherapy and 
radiotherapy, another folate-decorated LPHNP was designed 
by Werner et al and synthesized using nanoprecipitation tech-
nique to simultaneously encapsulate PCX and yittrium-90. 
Monodisperse hybrid NP contains a PLGA core and a 
shell of soybean lecithin, DMPE–DTPA, DSPE–PEG, and 
DSPE–PEG-folate. From in vivo efficacy studies using an 
ovarian peritoneal metastasis model, it is clearly evident that 
folate-targeted NPs containing dual chemoradiotherapeutics 
were noticeably more effective compared with nontargeted 
and single drug NPs.74 In 2015, using a thin-film hydration 
and ultrasonic dispersion method, Zhang et al prepared PCX-
loaded LPHNPs with a poly(ε-caprolactone)–poly(ethylene 
glycol)–poly(ε-caprolactone) (PCL-PEG-PCL) core, DSPE–
PEG
2000
 corona, and DSPE–PEG
2000
-folate active targeting 
ligand. In BALB/c mice bearing EMT6 (mammary carci-
noma cells) tumors, intratumoral delivery of PTX-loaded 
folate-targeted hybrid NPs showed lower toxicity but similar 
antitumor efficacy compared with Taxol® and greater thera-
peutic efficacy than nontargeted NPs.75 To circumvent the 
inherent limitations of cisplatin (chemotherapeutic) and ICG 
(photothermal therapeutic) delivery, in 2016, Gu et al derived 
Table 2 examples of targeted delivery approaches by LPHNPs
Polymer Lipid Targeting 
ligand
Drug Size 
(nM)
PDI Zeta 
potential 
(mV)
Cell/animal Ref.
PLGA Lecithin/PeG2000/DSPe–PeG2000-
FA
Folate Doxorubicin HCl 118 0.12 -8.5 KB; COS-7; 
KB xenograft 
mice
72
PLGA DLPC/DSPe–PeG2000/DSPe–
PeG2000-FA
Folate Docetaxel 263.6 0.16 -20.74 MCF-7; 
NIH/3T3
73
PCL-PeG-
PCL
PeG/DSPe–PeG2000/DSPe–
PeG2000-FA
Folate Pacitaxel 279.9 0.173 -17.5 eMT6 
xenograft mice
75
PLGA DSPe–PeG2000/lecithin/DSPe–
PeG2000-FA
Folate Cisplatin; ICG 90–100 0.2 -19.8 MCF-7 76
PLGA Lecithin/DSPe–PeG-COOH/
DSPe–PeG2000-FA
Folate Doxorubicin 118.7 0.104 15.19 MCF-7 77
PLA SPC/DPPe/DSPe–PeG-COOH/
DSPe–PeG2000-FA
Folate Mitomycin C 215.6 0.145 -25.88 HeLa; A549; 
H22 tumor rats
78
PLGA ePC/DSPe–PeG/DSPe/H2N-
PeG2K-OH
RGD 10-Hydroxycamptothecin 249 0.289 -25.6 MDA-MB-
435s; MCF-7
79
mPeG-
PLGA
Lecithin/cholesterol/Chol-PeG-
RGD
RGD Curcumin 216.6 0.205 -0.23 B16; HUveC 80
PLGA-
COOH
Lecithin/DSPe–PeG2000-Mal RGD Isoliquiritigenin 137.2 N/A -34.2 MDA-MB-231; 
MCF-7; 4T1 
xenograft mice
81
PLGA Lecithin/DSPe–PeG2000-OMe/
DSPe–PeG2000-RGD
RGD Docetaxel 110 0.132 -25.67 C6; GBM 
bearing rats
82
Abbreviations: DLPC, 1,2-dilauroylphosphatidylocholine; ICG, indocyanine green; LPHNPs, lipid–polymer hybrid nanoparticles; PCL–PeG–PCL, poly(ε-caprolactone)–
poly(ethylene glycol)–poly(ε-caprolactone); PDI, polydispersity index; PeG, polyethylene glycol.
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a folate-fabricated, cisplatin and ICG-loaded, homogeneous, 
stable LPHNPs using PLGA, lecithin, DSPE–PEG
2000
, and 
DSPE–PEG
2000
-FA by a single-step sonication method. 
Targeting efficiency of the folate-modified NPs was greater 
in folate receptor (FR) overexpressing MCF-7 cells than in 
FR-negative A549 cells. Moreover, treatment of targeted 
NPs with 808 nm near infra-red laser irradiation induced 
substantial cell death by apoptosis and necrosis of MCF-7 
cells compared with standard care therapy.76 Using an ESE 
technique, a DOX-encapsulated LPHNP was constructed 
with PLGA-lecithin-DSPE–PEG and further decorated with 
DSPE–PEG-folate. It had been shown that folate-targeted 
NPs confer higher uptake and cytotoxicity in MCF-7 cells 
compared with nontargeted NPs.77 In order to bypass the 
limitations of mitomycin C (a water-soluble antibacterial 
and antitumor agent), it was complexed with soy-PC and 
loaded onto a folate-functionalized LPHNP system having 
a PLA core and DPPE/DSPE–PEG/DSPE–PEG-folate shell 
using an ESE technique. Importantly, folate-decorated NPs 
markedly improved pharmacokinetic profile (compared with 
free drug) by extending circulation time and showed better 
in vitro and in vivo therapeutic efficiency.78
Targeted delivery by RGD
Yang et al, in 2013, used a modified single ESE method 
to produce an LPHNP with PLGA-EPC/DSPE–PEG and 
DSPE–PEG-c(RGDyk) to deliver 10-hydroxycamptothecin 
(HCPT) via targeting integrin α∨β3-positive cancer cells. 
They optimized DSPE–PEG:EPC molar ratio to be 5:5 and 
the lipids:PLGA mass ratio to be 1:15 with a zeta potential 
of about -26 mV and with an average size of 230 nm. They 
found an improved cytotoxicity profile of HCPT against 
MDA-MB-435s cells for the targeted NPs.79 Using a double 
ESE technique (w/o/w), RGD-functionalized polymer-core 
lipid-shell hybrid NPs were synthesized by Zhao et al in 2013. 
By the virtue of integrin recognition, these particles enhanced 
cytotoxicity of curcumin in vitro and demonstrated tumor 
growth inhibition and prolonged survival in a subcutaneous 
B16 murine tumor model.80 To amend the poor bioavailability 
of isoliquiritigenin (ISL), a natural antibreast cancer dietary 
compound, Gao et al recently developed iRGD (tumor-
homing peptide) decorated LPHNPs by a modified nano-
precipitation method using PLGA-lecithin/DSPE–PEG-Mal. 
A postinsertion approach (iRGD covalently grafted onto the 
PEG) was adopted to decorate the surface with iRGD pep-
tides. Surface-functionalized ISL-loaded NPs demonstrated 
better cytotoxicity and apoptotic cell death of different 
types of breast cancer cells, prolonged in vivo circulation, 
and exhibited higher tumor growth inhibition efficacy in 
4T1-bearing breast tumor murine models compared with 
the free drug and nontargeted counterparts.81 In a separate 
study, Shi et al developed RGD-modified LPHNPs for the 
delivery of docetaxel to glioblastoma multiforme, from the 
precursors PLGA-soy lecithin and DSPE–PEG (containing 
DSPE–PEG
2000
-RGD and DSPE–PEG
2000
 at a molar ratio 
of 8.5:1.5). After a series of experiments including cellular 
uptake, tumor spheroid penetration, and tumor growth inhi-
bition, a rat model of brain GBM was used to evaluate anti-
tumor efficacy of the RGD-functionalized docetaxel-loaded 
NPs where the median survival times for the rats treated with 
these particles were prolonged by 57 days.82
Other methods for active targeting
Besides folate and RGD-mediated delivery, few attempts 
have also been made using transferrin, antibodies, and aptam-
ers to target cancer cells. For example, Zheng et al followed 
a postinsertion method to develop a transferrin (Tf-DOPE) 
conjugated LPHNPs encapsulating aromatase inhibitor 
(7a-APTADD). Tf-conjugated NPs showed higher inhibition 
of aromatase in breast cancer cells (SKBR-3) than that by 
the nontargeted NPs.50 Again, Zhang et al covalently grafted 
amine-terminated A10 RNA aptamer to carboxyl functional-
ized lipid–PEG conjugates in order to target prostate-specific 
membrane antigen (PSMA) overexpressed in LNCaP cells. 
Aptamer-conjugated NBD-encapsulated hybrid NPs were 
successfully taken up by LNCaP via active-targeted mecha-
nism but not by PC3 cells, which do not express PSMA.27 
Utilizing single-step nanoprecipitation with the precursor 
PLGA-soy lecithin-DSPE–PEG/DSPE–PEG-Mal, Hu et al 
prepared a PTX-loaded LPHNP platform. A half-antibody 
displaying anticarcinoembryonic activity was conjugated 
to the hybrid NP via postinsertion to target carcinoembry-
onic antigen (CEA)-overexpressed pancreatic cancer cells. 
Antibody-conjugated NPs, thus synthesized, were shown to 
selectively target CEA-positive BxPC-3 pancreatic cancer 
cells resulting in an elevated cellular uptake and higher 
in vitro cytotoxicity compared with nontargeted NPs.83
siRNA delivery
RNAi is an evolutionarily conserved unique cellular surveil-
lance mechanism, with sequence-specific post-transcrip-
tional gene silencing capability. Ever since its disclosure in 
cultured mammalian cells and mammals, studies aimed at 
demonstrating the clinical potential of siRNAs have been 
reported in mouse models as well as in nonhuman primates 
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and more recently in humans.84 Global efforts have been 
witnessed in developing vectors for in vivo delivery of 
therapeutic siRNAs.85 Most recently, a lipid-based RNAi 
therapeutic (ONPATTRO™, Alnylam Pharmaceuticals 
Inc.) received FDA approval, which is the first of its cat-
egory, for the treatment of polyneuropathy of hereditary 
transthyretin-mediated amyloidosis in adults.86 Nevertheless, 
a few cellular as well as preclinical studies have already been 
performed for LPHNP-mediated RNAi. Here, we summarize 
a few of them.
With the precursors PLGA-DOPC/cyclic cationic lipid 
and DSPE−PEG
2000
, Desai et al formulated an LPHNP 
through single-step nanoprecipitation to simultaneously 
deliver an anti-inflammatory drug capsaicin and siRNA 
against TNF-α (siTNFα) to treat skin inflammatory condi-
tions under systemic settings. It was shown that the NPs 
could deliver capsaicin deep into dermal tissue (~360 µm), 
and its combination with siTNFα showed a synergistic effect 
on skin inflammation.87 In 2012, with cationic lipid (N,N-
bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryloxycarbonyl 
aminoethyl) ammonium bromide, BHEM-Chol) and PLGA 
polymers, LPHNPs were prepared by Yang et al for systemic 
delivery of siRNA by a modified nanoprecipitation method. 
NPs effectively delivered siPlk1 (targeted against Plk1 onco-
gene) to BT474 cells in vitro and BT474 xenograft murine 
model in vivo and inhibited tumor growth.49 In another study, 
siRNA was encapsulated within hybrid NPs prepared via 
modified double emulsion solvent evaporation technique. 
PLGA and a newly synthesized cationic lipid-like molecule 
(G0-C
14
) were taken to constitute the core to which siRNA 
was added and added together to DSPE–PEG and lecithin. 
NP-mediated delivery of siPHB1, which outcompetes 
standard lipofectamine complexes, resulted in long-term 
silencing of the prohibitin 1 gene and therefore effective 
tumor growth inhibition in vivo (A549 xenograft BALB/C 
nude mice model).88 Intending to develop a well-capable 
siRNA delivery platform, Shi et al proposed differentially 
charged hollow core/shell LPHNPs made by modified double 
emulsion solvent evaporation technique. Interestingly, GL3 
siRNA encapsulated within these hybrid NPs was success-
fully delivered to luciferase-expressing xenograft tumors of 
Dual-Luc HeLa cells and significantly reduced luciferase 
activity.89 Another siRNA delivery platform was created 
by Gao et al, wherein a cationic liposome made up of 
DOTAP:DOPE:cholesterol (25:43:25) was mixed with the 
anionic cholesterol-grafted poly(amidoamine)/siRNA, and 
the resulting LPHNP was further modified with DSPE–PEG/
DSPE–PEG-T7 (where T7= HAIYPRH). Efficacy study on 
nude mice bearing MCF-7 tumor xenografts further asserted 
that T7-modified siEGFR-loaded NPs demonstrated highest 
tumor growth inhibition via transferrin receptor-mediated 
active-targeted delivery.90
Imaging agent delivery
In recent years, owing to its stability and biocompatibility, 
LPHNPs have increasingly been used as a delivery system 
for contrast agents (quantum dots, inorganic nanocrystals), 
commonly used in bioimaging such as MRI and CT. For 
instance, Mieszawska et al designed a unique method to 
append diagnostic features to LPHNPs prepared via nano-
precipitation. They conjugated gold nanocrystals (AuNC) 
and quantum dots to the PLGA by esterification reactions 
and then mixed with soybean lecithin and PEG. The in vitro 
experiments in mouse macrophage (J774A.1) further sup-
ported the suitability of AuNC and quantum dots-loaded 
LPHNPs as probes for image generation in both biological 
and medical settings.32 A parallel approach was to form 
the core with polymers having high fluorescence. Using 
nanoprecipitation, LPHNPs are synthesized where the core 
is composed of PFBT with an envelope of DMPE–PEG. 
Notably, hybrid NPs showed ~50% higher quantum yield 
compared with their nonhybrid counterpart.53
Future possibilities
As evident from our prior discussion, one-step method is 
preferred over the two-step method due to its simplicity. 
Irrespective of the method of preparation, L/P ratio is found 
to be the most crucial formulation parameter to monitor size, 
homogeneity, %EE, release kinetics, while colloidal stability 
is critically dependent on the steric stabilization provided by 
the PEG fragment of the PEGylated lipid component. Sub-
categorically, within the realm of one-step method, despite 
higher content loading in the ESE method, nanoprecipitation 
is favored as it can produce sub-100 nm sized particles. Nano-
precipitation, thus, has advanced to large-scale production by 
a continuous high-throughput microfluidic process. Research 
endeavors in the near future will require an advancement of a 
continuous high-throughput microfluidic process for the ESE 
method as well. The ensuing challenge in large-scale pro-
duction of LPHNPs, in common with all other scale-up pro-
cesses, will be entrenching consistent production of particles 
with controlled size and homogeneity. Another task required 
for researchers in the field is to convert their liquid LPHNP 
formulations to dry powder form, while keeping all physical 
characteristics intact, which is essential for long-term stor-
age. This has previously been explored for liposomes and 
polymeric NPs.91,92 Conversion to dry powder, in general, is 
executed by lyophilization or spray-drying in the presence 
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of cryoprotectants. As is to be expected, optimizations of 
formulation parameters are required while deciding the 
method as well as the cryoprotectants.
Within the last 2 years, a number of new applications 
for the LPHNP platform have been demonstrated. Notably, 
these include photoresponsive LPHNPs for controlled release 
of doxorubicin, insulin delivery, delivery of mRNA to lung 
tissue, and MRI-guided targeted delivery of doxorubicin, 
among others.93–97 Although the voyage is commenced, step-
ping out beyond the realm of oncology is still at the juvenile 
stage for LPHNPs. Future directions of LPHNP research 
remain open to translate its potential into practice for many 
other disease models. For the delivery of genetic material, it is 
essential to clarify the reduction of nonspecific binding with 
serum proteins. Significant work is also required to establish 
reliable clinical applications for the delivery of diagnostic 
bioimaging agents. Advancements in clinical techniques for 
minimally invasive targeted delivery may also further extend 
the application of LPHNPs by maximizing therapeutic deliv-
ery and minimizing systemic exposure. One such approach, 
called convection-enhanced delivery (CED), involves the 
use of one or more microcatheters placed stereotactically 
into target tissues (eg, intratumorally or within the target 
brain regions) through which an infusate is actively pumped 
while maintaining a pressure gradient over multiple hours. 
A number of recent clinical trials using CED have shown 
the technique to be an effective option for the delivery of 
therapeutics with significantly greater volume of distribu-
tion vs standard diffusion-dependent delivery methods. As 
such, CED holds great potential in current and future clinical 
trial designs for improving the reliability of therapeutic 
delivery and limiting confounding due to variable target 
bioavailability. The combination of advanced minimally 
invasive techniques like CED with the improved therapeutic 
design offered by LPHNPs may offer synergistic potential 
in future clinical applications and is an area of great interest 
for future studies.98–100
Conclusion
LPHNPs have displayed a remarkable range of successes 
in translating new clinical and drug delivery applications 
from bench to bedside, with a significant and lasting impact 
in the field of oncology. Indeed, in some cases, LPHNPs 
have already demonstrated superiority compared with 
liposomes and polymeric NPs. From the perspective of 
industrial production and scalability, efficient and simple 
large-scale production of NPs has already been developed. 
As such, we predict ever-expanding applications for LPH-
NPs with many more translational opportunities for future 
clinical trials, including beyond active targeting of anticancer 
therapies in oncology toward more broad applications in 
medical therapies and neurotherapeutics as well as diagnostic 
imaging agents.
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